API | Coccidioides immitis Spherule - Derived Skin Test Antigen

Coccidioides immitis Spherule - Derived Skin Test Antigen (Spherusol) Report issue

Biological Orphan Drug ^FDA Approved ^FDA

AACT

Active Ingredient History

NOW

Coccidioides immitis is a pathogenic fungus that resides in the soil in certain parts of the southwestern United States, northern Mexico, and a few other areas in the Western Hemisphere. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Drug Pricing (per unit)

United States

$601.1500 - $740.2900

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

coccidioides immitis spherule-derived skin test antigen | coccidioidin | spherusol

Organizations (6)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (1)

Diagnosis (approved 2011)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Coccidioidomycosis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue